Summit Therapeutics Files 8-K

TL;DR

Summit Therapeutics filed a standard 8-K, no major news.

AI Summary

Summit Therapeutics Inc. filed an 8-K on May 24, 2024, reporting other events and financial statements. The company, incorporated in Delaware, has its principal executive offices in Miami, Florida. This filing does not appear to contain specific material events or financial figures beyond the standard reporting requirements.

Why It Matters

This filing indicates routine corporate reporting by Summit Therapeutics Inc. to the SEC, without disclosing specific new material events.

Risk Assessment

Risk Level: low — The filing is a routine 8-K and does not disclose any new material events, risks, or financial changes.

Key Players & Entities

• Summit Therapeutics Inc. (company) — Registrant
• May 24, 2024 (date) — Date of Report
• Delaware (jurisdiction) — State of Incorporation
• Miami, FL (location) — Principal Executive Offices
• 001-36866 (other) — SEC File Number

FAQ

Key Financial Figures

• $0.01 — ange on Which Registered Common stock, $0.01 par value per share SMMT The Nasdaq Sto

Filing Documents

• smmt-20240524.htm (8-K) — 32KB
• 0001599298-24-000092.txt ( ) — 183KB
• smmt-20240524.xsd (EX-101.SCH) — 2KB
• smmt-20240524_def.xml (EX-101.DEF) — 14KB
• smmt-20240524_lab.xml (EX-101.LAB) — 25KB
• smmt-20240524_pre.xml (EX-101.PRE) — 15KB
• smmt-20240524_htm.xml (XML) — 3KB

01 Other Events

Item 8.01 Other Events. On May 24, 2024, the National Medical Products Administration (NMPA), the regulatory authority in China responsible for providing marketing authorization for clinical drug candidates, has approved ivonescimab in combination with chemotherapy for use in patients with epidermal growth factor receptor (EGFR) mutated, locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) who have progressed after treatment with an EGFR tyrosine kinase inhibitor (TKI). This is the first approval for ivonescimab by any regulatory authority. The approval for ivonescimab was based on the trial called HARMONi-A (AK112-301), a single region Phase III clinical trial conducted in China comparing ivonescimab plus chemotherapy vs. placebo plus chemotherapy in the aforementioned setting. The trial was sponsored by our partner, Akeso, Inc. (Akeso). Data for this trial was generated and analyzed by Akeso. This data is planned to be released at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting during an oral presentation on Friday, May 31, 2024, scheduled for 4:57pm CT. On May 23, 2024, ASCO released abstracts for presentations to take place during the Annual Meeting. Included in these abstracts, was topline data associated with HARMONi-A. Notably, patients receiving ivonescimab plus chemotherapy experienced a median progression free survival (PFS) by independent radiology review committee (IRRC) of 7.06 months (95% CI: 5.85 – 8.74) as compared to 4.80 months (95% CI: 4.21 – 5.55) for those patients receiving chemotherapy alone (hazard ratio: 0.46; 95% CI: 0.34 – 0.62). Grade 3 treatment emergent adverse events (TEAEs) occurred in 61.5% patients receiving ivonescimab plus chemotherapy as compared to 49.1% patients receiving chemotherapy; the most common grade 3 TEAEs were chemotherapy related adverse events. Additional data and context including, but not limited to, response rates, stable disease rates, progression free sur

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized. SUMMIT THERAPEUTICS INC. Date: May 24, 2024 By: /s/ Manmeet S. Soni Chief Operating Officer and Chief Financial Officer (Principal Financial Officer)

View Full Filing

View this 8-K filing on SEC EDGAR